Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

NCT02345863 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leucemia

Interventions

DRUG: Bendamustine
DRUG: GA101
DRUG: Ibrutinib

Sponsor

German CLL Study Group

Collaborators

[object Object]
[object Object]